Pharma & Biotech

Trontinemab Brainshuttle Study Achieves 91 Percent Amyloid Clearance and Sets Stage for 2025 Phase III Rollout

(IN BRIEF) Roche’s ongoing Phase Ib/IIa Brainshuttle™ AD study of trontinemab shows that 91 percent of participants reach amyloid PET negativity, with…

2 months ago

EMA Recommends Approval of Pfizer-BioNTech’s LP.8.1 COVID-19 Vaccine for Broad Use in EU

(IN BRIEF) Pfizer and BioNTech have received a positive recommendation from the EMA’s CHMP for their LP.8.1-adapted monovalent COVID-19 vaccine,…

2 months ago

CHMP Recommends Expanding Novo Nordisk’s Alhemo® Access to Broader Haemophilia Population Without Inhibitors

(IN BRIEF) Novo Nordisk has received a positive opinion from the European Medicines Agency’s CHMP recommending label expansion for Alhemo®…

2 months ago

Sanofi Gains EU Approval for Sarclisa in First-Line Treatment of Transplant-Eligible Multiple Myeloma

(IN BRIEF) Sanofi has secured European Commission approval for Sarclisa in combination with VRd as an induction treatment for newly…

2 months ago

Final FLAURA2 Results Confirm Survival Advantage of Tagrisso Plus Chemotherapy in Advanced EGFRm Lung Cancer

(IN BRIEF) Final overall survival results from AstraZeneca’s FLAURA2 Phase III trial confirm that combining Tagrisso with chemotherapy significantly improves…

2 months ago

Sanofi Finalizes Blueprint Medicines Deal Adding Ayvakit and Robust SM Pipeline

(IN BRIEF) Sanofi has completed its purchase of Blueprint Medicines, acquiring the approved systemic mastocytosis therapy Ayvakit/Ayvakyt (avapritinib), along with…

3 months ago